<DOC>
	<DOCNO>NCT00951015</DOCNO>
	<brief_summary>This Phase IIb study HIV-infected antiretroviral naive subject select optimal daily dose GSK1349572 range dose future evaluation .</brief_summary>
	<brief_title>A Dose Ranging Trial GSK1349572 2 NRTI HIV-1 Infected , Therapy Naive Subjects</brief_title>
	<detailed_description>This Phase IIb study HIV-infected antiretroviral naive adult subject include dose-ranging evaluation GSK1349572 10mg , 25mg 50mg daily blind dos control arm open label efavirenz 600mg daily . Background ART study subject choose investigator either Truvada Epzicom/Kivexa . Data three dos GSK1349572 compare basis antiviral activity , safety/tolerability pharmacokinetics 16-24 week . Several plan interim analysis evaluate data real time ; dos consider inferior drop subject dose GSK1349572 option switch either high dose still investigation select dose . Subjects able remain study , unless reach stop criterion , least 96 week . ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<criteria>HIV1 infect male female adult least 18 year age . Women capable become pregnant must use appropriate contraception study ( define protocol ) ; HIV1 infection screen plasma HIV1 RNA great equal 1000copies/mL ; CD4+ cell count great equal 200cells/mm3 ( high local guideline dictate ) ; ARTnaive ( less equal 10 day prior therapy antiretroviral agent ) . Any previous exposure HIV integrase inhibitor GSK1349572 exclusionary . No evidence viral resistance antiretroviral drug indicative primary transmit resistance screening ; Able understand comply protocol requirement ; Able provide write informed consent prior screen ; French subject : In France , subject eligible inclusion study either affiliate beneficiary social security category . Note : Subjects start abacavir part NRTI backbone must screen negative HLAB*5701 allele . Any preexist serious mental physical disorder could compromise ability comply protocol compromise subject safety ; Women pregnant breastfeeding ; An active AIDSdefining condition screen visit ; Previous participation experimental drug and/or vaccine trial ( ) within 30 day 5 halflives ; History clinically relevant pancreatitis hepatitis within previous 6 month , include HBsAg positive result . Asymptomatic HCV infection exclusionary , however subject require HCV therapy trial exclude . Any subject history liver cirrhosis without hepatitis viral coinfection exclude . Any condition could interfere absorption , distribution , metabolism excretion drug ; Any acute Grade 4 laboratory abnormality screening ; History upper gastrointestinal bleed and/or subject active peptic ulcer disease ; Estimated creatinine clearance &lt; 50 mL/min ; Alanine aminotransferase ( ALT ) great equal 5 time ULN ; Alanine aminotransferase ( ALT ) great equal 3xULN bilirubin great equal 1.5xULN ( &gt; 35 % direct bilirubin ) ; Lipase great equal 3xULN ; Hemoglobin &lt; 100 g/L ( 10 g/dL ) ; History allergy study drug component drug class ; Treatment radiation therapy , cytotoxic chemotherapeutic agent , agent activity HIV1 immunomodulators within 28 day prior screen ; Treatment HIV1 immunotherapeutic vaccine within 90 day prior screen ; History protocoldefined cardiac disease ; Personal family history prolong QT syndrome ; Any clinically significant finding , specify protocol , electrocardiograph ( ECG ) ; Significant blood loss excess 500 mL within 56 day period prior screen visit ; Immunization within 30 day prior first dose investigational product ; French subject : The subject participate study use investigational drug previous 60 day 5 halflives , twice duration biological effect experimental drug vaccine whichever longer , prior screen study subject participate simultaneously another clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>GSK1349572</keyword>
	<keyword>emtricitabine</keyword>
	<keyword>tenofovir</keyword>
	<keyword>efavirenz</keyword>
	<keyword>abacavir</keyword>
	<keyword>antiretroviral therapy naive</keyword>
	<keyword>dose selection</keyword>
	<keyword>HIV-1 Infection</keyword>
	<keyword>integrase inhibitor</keyword>
	<keyword>HIV infection</keyword>
	<keyword>daily</keyword>
	<keyword>lamivudine</keyword>
</DOC>